New Pill Doubles Survival in Pancreatic Cancer Trials
A new pill, daraxonrasib, reportedly doubles survival in early pancreatic cancer trials. Revolution Medicines targets KRAS gene. Learn more at TinyGems.
This news matters because pancreatic cancer is notoriously deadly, with few effective treatments. If confirmed, daraxonrasib could offer new hope to thousands of patients, representing a major breakthrough in oncology. The progress also highlights the potential of targeted therapies against previously 'undruggable' targets like KRAS.
